Form 4: Allogene Therapeutics Director Deborah Messemer Sells Shares Under 10b5-1 Trading Plan

Director Deborah Messemer sold 18,641 shares of Allogene Therapeutics (ALLO) common stock at a weighted average price of $2.2793 per share on June 18, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 18, 2024, Deborah Messemer, a director of Allogene Therapeutics, sold 18,641 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• The shares were sold at a weighted average price of $2.2793, with individual prices ranging from $2.25 to $2.30.
• Following the transaction, Messemer directly owns 166,765 shares of Allogene Therapeutics.
• Messemer has granted a power of attorney to Earl Douglas, Geoffrey Parker, Annie Yoshiyama, and Lillian Smith to execute and file SEC forms on her behalf.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale was conducted under a pre-arranged 10b5-1 trading plan, which mitigates negative interpretations. However, any insider selling can raise concerns, even if pre-planned.

Positives

• The sale was conducted under a pre-existing 10b5-1 trading plan, which can mitigate concerns about insider trading as the plan was established well in advance of the transaction.

Negatives

• The sale of shares by a director could be perceived negatively by investors, although the existence of a 10b5-1 plan may alleviate some concerns.

Risks

• Continued sales by insiders, even under 10b5-1 plans, could exert downward pressure on the stock price.
• Negative investor sentiment could arise if the market interprets the sale as a lack of confidence in the company's future prospects, despite the pre-planned nature of the transaction.

Industry Context

Sales by insiders are a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a recognized method for insiders to sell shares while avoiding accusations of trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Comparison to Industry Standards

• Comparing Allogene's insider trading activity to similar biotech companies like CRISPR Therapeutics or Editas Medicine would provide context.
• Analyzing the frequency and size of insider sales across these companies can help determine if Allogene's activity is typical.
• Benchmarking against industry averages for insider selling as a percentage of total shares outstanding can also be informative.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan may lessen concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates